Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Carcinoma, Small Cell, Small Cell Lung Carcinoma, Prostatic Neoplasms, Castration-Resistant

NCT05746481 2026-01-22

Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases

Phase 2 Terminated

3 enrolled 12 charts

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT03425331 2026-01-08

Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC

Phase 2 Terminated

5 enrolled 13 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04966676 2026-01-08

ATLAS

Phase 2 Terminated

5 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05141357 2025-12-24

HBI-8000

Phase 2 Terminated

5 enrolled 8 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04765709 2025-12-16

BRIDGE

Phase 2 Terminated

10 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04916002 2025-12-05

A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer

Phase 2 Terminated

77 enrolled 18 charts

BreastDermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Basal Cell, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Carcinoma, Merkel Cell, Triple Negative Breast Neoplasms

NCT04549428 2025-11-18

Atezolizumab Plus 8 Gy Single-fraction Radiotherapy for Advanced Oligoprogressive NSCLC

Phase 2 Terminated

12 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05256381 2025-11-17

A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors

Phase 2 Terminated

166 enrolled 43 charts

GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Ovarian Neoplasms, Colorectal Neoplasms

NCT05513703 2025-10-24

A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Terminated

9 enrolled 13 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT05846646 2025-10-20

Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC

Phase 2 Terminated

6 enrolled 7 charts

GenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell

NCT04926831 2025-10-16

Geometry-N

Phase 2 Terminated

4 enrolled 10 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03237377 2025-10-14

Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer

Phase 2 Terminated

9 enrolled 12 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04914897 2025-10-02

A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)

Phase 2 Terminated

106 enrolled 21 charts

Other solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung

NCT04985604 2025-10-02

Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors

Phase 2 Terminated

23 enrolled 15 charts

CNSDermatologicEndocrineGastrointestinalGenitourinaryHead & NeckThoracic

Thyroid Cancer, Papillary, Astrocytoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Pancreatic Neoplasms, Colorectal Neoplasms

NCT05577715 2025-09-04

A Study of MORAb-202 in Participants With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC)

Phase 2 Terminated

31 enrolled 12 charts

Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung

NCT04581824 2025-08-08

Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)

Phase 2 Terminated

243 enrolled 21 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05617313 2025-07-30

Study of GT103 in Combination With Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer

Phase 2 Terminated

21 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05691829 2025-07-29

IRRADIATE-Lung

Phase 2 Terminated

19 enrolled 11 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT03087708 2025-07-17

Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer

Phase 2 Terminated

50 enrolled 24 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05563272 2025-07-10

STARBURST

Phase 2 Terminated

11 enrolled

CNSGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Nasopharyngeal Carcinoma, Mesothelioma, Malignant, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Carcinoma, Hepatocellular, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma, Small Cell Lung Carcinoma

NCT03777124 2025-07-04

Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer

Phase 2 Terminated

25 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03505710 2025-05-30

DESTINY-Lung01

Phase 2 Terminated

181 enrolled 17 charts 2 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT04441138 2025-05-28

ESR1814205

Phase 2 Terminated

10 enrolled 11 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02093962 2025-05-16

Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer

Phase 2 Terminated

265 enrolled 8 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06003075 2025-04-30

Induction Chemo-Nivo in Unresectable Stage III NSCLC

Phase 2 Terminated

1 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05275673 2025-04-24

A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer

Phase 2 Terminated

7 enrolled 11 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Recurrence

NCT04892472 2025-04-23

KEYNOTE B36

Phase 2 Terminated

15 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04925986 2025-04-17

Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC

Phase 2 Terminated

9 enrolled 15 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms

NCT03445000 2025-04-08

ALERT-lung

Phase 2 Terminated

14 enrolled 14 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04512430 2025-04-02

Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients

Phase 2 Terminated

4 enrolled 9 charts

Thoracic

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT04629339 2025-03-13

Study of INCB086550 in Select Solid Tumors

Phase 2 Terminated

16 enrolled 17 charts

DermatologicGastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis

NCT04032704 2025-03-10

A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

Phase 2 Terminated

205 enrolled 54 charts

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Melanoma, Prostatic Neoplasms, Small Cell Lung Carcinoma

NCT03496766 2025-03-05

Tipifarnib in Advanced Squamous NSCLC With Oncogen HRAS MutAtionS

Phase 2 Terminated

9 enrolled 22 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04495894 2025-03-04

Pre-Incisional Ketorolac for Patients Undergoing Surgery for Non-Small Cell Lung Cancer and Renal Cell Carcinoma

Phase 2 Terminated

68 enrolled 14 charts

GenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell

NCT06191250 2025-02-03

--SuPERIOR Trial--

Phase 2 Terminated

10 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03705403 2025-01-30

IMMUNOSABR2

Phase 2 Terminated

88 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT04856176 2025-01-01

A Study of Sargramostim Plus Pembrolizumab with or Without Pemetrexed in Patients with Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy

Phase 2 Terminated

5 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04515979 2024-12-09

Vactosertib in Combination with Pembrolizumab for PD-L1 Positive Non-small Cell Lung Cancer (NSCLC) Subjects

Phase 2 Terminated

11 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02500927 2024-11-20

A Study of ASP8273 in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-Naïve Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations

Phase 2 Terminated

31 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05012397 2024-10-17

Milademetan in Advanced/Metastatic Solid Tumors

Phase 2 Terminated

40 enrolled 13 charts

DermatologicEndocrineGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Testicular Germ Cell Tumor, Adenocarcinoma of Lung, Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Stomach Neoplasms, Adrenocortical Carcinoma, Cholangiocarcinoma

NCT01088906 2024-10-15

Phalcis

Phase 2 Terminated

57 enrolled 18 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03207867 2024-10-09

A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma

Phase 2 Terminated

315 enrolled 73 charts

BreastDermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Pancreatic Neoplasms, Spinocerebellar Degenerations, Triple Negative Breast Neoplasms

NCT04139317 2024-10-09

Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50%

Phase 2 Terminated

76 enrolled 17 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04323436 2024-10-09

Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations

Phase 2 Terminated

31 enrolled 21 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

Clinical Trials

PIPSeN

A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer

OPTIMUNELUNG

Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC

Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung Cancer

Tamarack

Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases

Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC

ATLAS

HBI-8000

BRIDGE

A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer

Atezolizumab Plus 8 Gy Single-fraction Radiotherapy for Advanced Oligoprogressive NSCLC

A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors

A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC

Geometry-N

Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer

A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)

Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors

A Study of MORAb-202 in Participants With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC)

Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)

Study of GT103 in Combination With Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer

IRRADIATE-Lung

Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer

STARBURST

Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer

DESTINY-Lung01

ESR1814205

Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer

Induction Chemo-Nivo in Unresectable Stage III NSCLC

A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer

KEYNOTE B36

Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC

ALERT-lung

Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients

Study of INCB086550 in Select Solid Tumors

A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

Tipifarnib in Advanced Squamous NSCLC With Oncogen HRAS MutAtionS

Pre-Incisional Ketorolac for Patients Undergoing Surgery for Non-Small Cell Lung Cancer and Renal Cell Carcinoma

--SuPERIOR Trial--

IMMUNOSABR2

A Study of Sargramostim Plus Pembrolizumab with or Without Pemetrexed in Patients with Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy

Vactosertib in Combination with Pembrolizumab for PD-L1 Positive Non-small Cell Lung Cancer (NSCLC) Subjects

A Study of ASP8273 in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-Naïve Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations

Milademetan in Advanced/Metastatic Solid Tumors

Phalcis

A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma

Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50%

Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations